Kinnate Biopharma Inc expected to post a loss of 64  cents a share - Earnings Preview

Kinnate Biopharma

13/05/2022 21:05

* Kinnate Biopharma Inc  KNTE.OQ   KNTE.O  is expected
to show no
change in quarterly revenue when it reports  results 
    * ​Refinitiv's mean analyst estimate for Kinnate Biopharma
Inc is
for a loss of 64 cents per share. For the same quarter last
year, the company reported a loss of 49 cents per share.
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 7 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had fallen by
about 3.5%
in the last three months. ​
    * Wall Street's median 12-month price target for Kinnate
Biopharma
Inc is $39.5​, above​ its last closing price of $8.63. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2022  -0.62       -0.61                        
 Dec. 31 2022  -0.60       -0.59      -0.60     Missed  -2.2
 Sep. 30 2021  -0.55       -0.54      -0.57     Missed  -5.6​
 Jun. 30 2021  -0.44       -0.43      -0.49     Missed  -14
 ​​Mar.        -0.36       -0.36      -0.40     Missed  -10.3
 31 2021                                                
 Dec. 31 2020  -0.37       -0.37      -0.32     Beat    14.1​
 This summary was machine generated May 13 at 20:05 GMT.  All
figures in US dollars  unless otherwise stated